Studies Suggest Peptide May Benefit Idiopathic Pulmonary Fibrosis Patients
Two posters presented at ATS 2025 offered data on Rein Therapeutics' novel peptide LTI-03's potential clinical value for idiopathic pulmonary fibrosis patients.
Tag: pulmonary fibrosis and IPF
All
Latest
Studies Suggest Peptide May Benefit Idiopathic Pulmonary Fibrosis Patients
Two posters presented at ATS 2025 offered data on Rein Therapeutics’ novel peptide LTI-03’s potential clinical value for idiopathic pulmonary fibrosis patients.
Read More
Cancer Drug May Have Applications for Pulmonary Fibrosis
An FDA-approved cancer drug may help the immune system clear out damaged cells that cause the lung scarring, potentially restoring lung function in patients with pulmonary fibrosis.
Read More
Immune Cell Networks Drive Pulmonary Fibrosis
Networks of misplaced immune cells drive idiopathic pulmonary fibrosis — a discovery that may create a pathway to new treatments.
Read More
Surprisingly, Post-COVID-19 Pulmonary Fibrosis Tends to Resolve
Pulmonary fibrosis caused by severe COVID-19 shows a surprising tendency to resolve, offering new insights that may inform treatments for non-resolving forms of the disease.
Read More
Investigational Deupirfenidone Outperforms Pirfenidone in Phase 2b Trial for IPF
Deupirfenidone showed an 80.9% treatment effect compared to placebo at the higher dose studied, while pirfenidone had a 54.1% treatment effect versus placebo.
Read More
Pulmonary Fibrosis Foundation Launches Educational Resource for Newly Diagnosed Patients
The online resource aims to offer patients with pulmonary fibrosis and interstitial lung disease guidance and support in the early months after diagnosis.
Read More
World Oxygen Day Sparks Renewed Calls for Congressional Action on Supplemental Oxygen Access
Healthcare organizations are urging Congress to pass the SOAR Act to ensure Medicare patients have access to the supplemental oxygen they need for improved health and mobility.
Read More
Why Aren’t Some Long COVID Patients’ Lungs Healing?
A new study reveals that immune cells, typically involved in lung repair, may instead drive persistent damage and fibrosis in COVID patients, preventing proper healing.
Read More
Investigational Antibody Treatment Shows Promise for Fibrotic Lung Diseases
Preclinical data reveals CAN10’s potential to target key proteins involved in systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis.
Read More
Chinese Medicinal Fungus Alleviates Idiopathic Pulmonary Fibrosis in Mice
Cordyceps sinensis, a traditional Chinese medicinal fungus, alleviated IPF in mice by inhibiting mitochondrion-mediated oxidative stress.
Read More
COVID-19 Lung Recovery Shows Surprising Regression
A study reveals long-term lung abnormalities in severe COVID-19 patients, with some showing initial recovery followed by deterioration two years later.
Read More
Pulmonary Fibrosis Foundation Taps Next President and CEO
The Pulmonary Fibrosis Foundation has announced the appointment of a new president and CEO, following a period of interim leadership.
Read More
New Online Resource Aims to Improve Lives of Lung Disease Patients
The American Lung Association’s new Wellness Hub offers free resources designed to enhance the physical and mental well-being of lung disease patients.
Read More
Agomab’s IPF Drug Receives FDA Orphan Drug Designation
Agomab Therapeutics received FDA Orphan Drug Designation for AGMB-447, an inhaled lung-restricted ALK5-inhibitor for idiopathic pulmonary fibrosis.
Read More
FDA Grants Orphan Drug Designation to Inhaled Treatment for IPF
AGMB-447, a small-molecule inhibitor of ALK5, is being evaluated in a phase 1 clinical trial.
Read More
Investigational Drug for Pulmonary Fibrosis Fails in Phase 3 Trial
A multinational clinical trial found that the drug candidate did not significantly slow the progression of idiopathic pulmonary fibrosis compared to a placebo.
Read More
Body’s Own Healing Mechanisms Could Reverse Lung Fibrosis
Researchers have identified a molecular pathway that leverages the body’s natural healing processes to potentially reverse idiopathic pulmonary fibrosis.
Read More
Congress Introduces SOAR Act to Improve Supplemental Oxygen Access
The Supplemental Oxygen Access Reform Act of 2024, designed to ease access to supplemental oxygen for Medicare beneficiaries, was introduced in the US House of Representatives by a bipartisan group of members of Congress.
Read More
Five PFF Scholars Receive $100K Grants to Advance Pulmonary Fibrosis Research
Five PFF Scholars will each receive a $100,000 research grant over two years to improve the understanding of pulmonary fibrosis and advance successful treatments.
Read More
Certain Mouth Bacteria Linked to Pulmonary Fibrosis Survival
Surprisingly, one bacterial species tended to dominate in certain patients with IPF who were not treated with antibiotics—and those patients were more likely to survive.
Read More
Calluna Pharma Launches with €75M for Inflammatory and Fibrotic Disease Therapies
The new company, formed through a merger between Oxitope and Arxx, has a pipeline of selective antibodies that target inflammatory and fibrotic indications, including several first-in-class clinical candidates.
Read More
Morphine Therapy Reduced Chronic Cough in IPF Patients
Eighty-five percent of idiopathic pulmonary fibrosis patients suffer from chronic cough, but low-dose, controlled morphine may offer some relief.
Read More
FDA Clears AI-Powered Idiopathic Pulmonary Fibrosis Diagnostic
According to Imvaria, the device’s manufacturer, the clearance signifies the first FDA authorization of a diagnostic tool of any type in lung fibrosis.
Read More
Omega-3 Fatty Acids May Slow Pulmonary Fibrosis
Higher levels of omega-3 fatty acids were associated with better lung function and longer transplant-free survival in patients with pulmonary fibrosis, a new study finds.
Read More